NCT03988595
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be within 6 months of initiating first line endocrine therapy (tamoxifen, aromatase inhibitor, or fulvestrant) with CDK4/6 inhibition (palbociclib, ribociclib, or abemaciclib); Patients with treated and stable brain lesions of a duration of greater than or equal to 2 months may be enrolled
Exclusions: Patients participating in weight loss or other exercise programs at the same time
https://ClinicalTrials.gov/show/NCT03988595